

MDM2 (Phospho-Ser186/Ser188) Antibody

Catalog No: #11702



Package Size: #11702-1 50ul #11702-2 100ul

Orders: order@signalwayantibody.comSupport: tech@signalwayantibody.com

Description


Product Name	MDM2 (Phospho-Ser186/Ser188) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
Applications	IF
Species Reactivity	Hu
Specificity	The antibody detects endogenous levels of MDM2 only when phosphorylated at serine 186 and serine 188.
Immunogen Type	Peptide-KLH
Immunogen Description	Peptide sequence around phosphorylation site of Ser186/Ser188(H-K-S(p)-D-S(p)-I-S) derived from Human MDM2.
Target Name	MDM2
Modification	Phospho
Other Names	Oncoprotein Mdm2; p53-binding protein Mdm2; Ubiquitin-protein ligase E3 Mdm2;
Accession No.	Swiss-Prot#: Q00987; NCBI Gene#: 4193; NCBI Protein#: NP_001138811.1.
Uniprot	Q00987
GeneID	4193;
SDS-PAGE MW	55kd
Concentration	1.0mg/ml
Formulation	Rabbit IgG in phosphate buffered saline (without Mg ²⁺ and Ca ²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C/1 year

Application Details

Immunofluorescence: 1:100~1:200

Images

Immunofluorescence staining of methanol-fixed HeLa cells using MDM2 (Phospho-Ser186/Ser188) Antibody #11702.



Background

This gene is a target gene of the transcription factor tumor protein p53. The encoded protein is a nuclear phosphoprotein that binds and inhibits transactivation by tumor protein p53, as part of an autoregulatory negative feedback loop. Overexpression of this gene can result in excessive inactivation of tumor protein p53, diminishing its tumor suppressor function. This protein has E3 ubiquitin ligase activity, which targets tumor protein p53 for proteasomal degradation. This protein also affects the cell cycle, apoptosis, and tumorigenesis through interactions with other proteins, including retinoblastoma 1 and ribosomal protein L5. More than 40 different alternatively spliced transcript variants have been isolated from both tumor and normal tissues

M Zhou, *Blood*, Mar 1995; 85: 1608 - 1614.

Susan M. Mendrysa, *Mol. Cell. Biol.*, Mar 2000; 20: 2023 - 2030.

M. Saeed Sheikh, *Cancer Res.*, Jul 1993; 53: 3226 - 3228.

Note: This product is for in vitro research use only